Brief: Lakefront Biotherapeutics H1 Net Profit From Continuing Operations €15.8 Mln
BRIEF-Lakefront Biotherapeutics H1 Net Profit From Continuing Operations €15.8 Mln Aug 11 (Reuters) - Lakefront Biotherapeutics NV LKFT.AS:
REPORTED ON MONDAY H1 TOTAL NET REVENUE €18.6 MLN
H1 OPERATING LOSS €107.2 MLN
H1 NET PROFIT FROM CONTINUING OPERATIONS €15.8 MILLION
CONFIRMS 2026 CASH AND FINANCIAL INVESTMENT BALANCE GUIDANCE
GUIDANCE INCLUDES €50 MILLION SHARE REPURCHASE PROGRAM
FORECASTS HAVING AT LEAST €1.6 BLN OF ITS CASH REMAINING FOR ADDITIONAL STRATEGIC TRANSACTIONS AND OTHER CAPITAL ALLOCATION PRIORITIES FOLLOWING FUNDING PORTFOLIO TO FIRST GAMGERTAMIG APPROVAL
FINANCIAL INVESTMENTS AND CASH AND CASH EQUIVALENTS TOTALLED €2,239.5 MILLION ON JUNE 30
H1 TOTAL NET DECREASE IN CASH AND CASH EQUIVALENTS AND FINANCIAL INVESTMENTS AMOUNTED TO €758.5 MILLION
Source text: ID: nGNE7zg9xq
Further company coverage: LKFT.AS
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Lakefront Biotherapeutics NV
See all newsBrief: Lakefront Announces Sale Of Preclinical Car-T Programs To Armed Cell Therapeutics
RBC upgrades Lakefront Biotherapeutics to 'outperform' on gamgertamig prospect
Brief: U.S. FDA Grants Orphan Drug Designation To Gamgertamig For The Treatment Of Pemphigus
Brief: Lakefront Biotherapeutics H1 Net Profit From Continuing Operations €15.8 Mln
Brief: Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline